HemaSphere最新文献

{"title":"Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma","authors":"Larissa Haertle,&nbsp;Umair Munawar,&nbsp;Hipólito N. C. Hernández,&nbsp;Andres Arroyo-Barea,&nbsp;Tobias Heckel,&nbsp;Isabel Cuenca,&nbsp;Lucia Martin,&nbsp;Carlotta Höschle,&nbsp;Nicole Müller,&nbsp;Cornelia Vogt,&nbsp;Thorsten Bischler,&nbsp;Paula L. del Campo,&nbsp;Seungbin Han,&nbsp;Natalia Buenache,&nbsp;Xiang Zhou,&nbsp;Florian Bassermann,&nbsp;Johannes Waldschmidt,&nbsp;Torsten Steinbrunn,&nbsp;Leo Rasche,&nbsp;Thorsten Stühmer,&nbsp;Joaquin Martinez-Lopez,&nbsp;K. Martin Kortüm,&nbsp;Santiago Barrio","doi":"10.1002/hem3.110","DOIUrl":"10.1002/hem3.110","url":null,"abstract":"<p>Multiple myeloma (MM) is a genetically heterogeneous disease and the management of relapses is one of the biggest clinical challenges. <i>TP53</i> alterations are established high-risk markers and are included in the current disease staging criteria. <i>KRAS</i> is the most frequently mutated gene affecting around 20% of MM patients. Applying Clonal Competition Assays (CCA) by co-culturing color-labeled genetically modified cell models, we recently showed that mono- and biallelic alterations in <i>TP53</i> transmit a fitness advantage to the cells. Here, we report a similar dynamic for two mutations in <i>KRAS</i> (G12A and A146T), providing a biological rationale for the high frequency of <i>KRAS</i> and <i>TP53</i> alterations at MM relapse. Resistance mutations, on the other hand, did not endow MM cells with a general fitness advantage but rather presented a disadvantage compared to the wild-type. <i>CUL4B</i> KO and <i>IKZF1</i> A152T transmit resistance against immunomodulatory agents, <i>PSMB5</i> A20T to proteasome inhibition. However, MM cells harboring such lesions only outcompete the culture in the presence of the respective drug. To better prevent the selection of clones with the potential of inducing relapse, these results argue in favor of treatment-free breaks or a switch of the drug class given as maintenance therapy. In summary, the fitness benefit of <i>TP53</i> and <i>KRAS</i> mutations was not treatment-related, unlike patient-derived drug resistance alterations that may only induce an advantage under treatment. CCAs are suitable models for the study of clonal evolution and competitive (dis)advantages conveyed by a specific genetic lesion of interest, and their dependence on external factors such as the treatment.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?","authors":"Baptiste Le Calvez,&nbsp;Maxime Jullien,&nbsp;Jean H. Dalle,&nbsp;Cécile Renard,&nbsp;Charlotte Jubert,&nbsp;Arthur Sterin,&nbsp;Catherine Paillard,&nbsp;Anne Huynh,&nbsp;Sarah Guenounou,&nbsp;Bénédicte Bruno,&nbsp;Virginie Gandemer,&nbsp;Nimrod Buchbinder,&nbsp;Pauline Simon,&nbsp;Cécile Pochon,&nbsp;Anne Sirvent,&nbsp;Dominique Plantaz,&nbsp;Justyna Kanold,&nbsp;Marie C. Béné,&nbsp;Fanny Rialland,&nbsp;Audrey Grain,&nbsp;Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)","doi":"10.1002/hem3.120","DOIUrl":"10.1002/hem3.120","url":null,"abstract":"<p>For most patients with childhood myelodysplastic syndrome (cMDS), allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option. In the case of increased blasts (cMDS-IB), the benefit of pretransplant cytoreductive therapy remains controversial. In this multicenter retrospective study, the outcomes of all French children who underwent allo-HSCT for cMDS reported in the SFGM-TC registry between 2000 and 2020 were analyzed (<i>n</i> = 84). The median age at transplantation was 10.2 years. HSCT was performed from matched sibling donors (MSD) in 29% of the cases, matched unrelated donors (MUD) in 44%, haploidentical in 6%, and cord blood in 21%. Myeloablative conditioning was used in 91% of cases. Forty-eight percent of patients presented with cMDS-IB at diagnosis (median BM blasts: 8%). Among them, 50% received pretransplant cytoreductive therapy. Five-year overall survival (OS), cumulative incidence of nonrelapse mortality (NRM), and relapse were 67%, 26%, and 12%, respectively. Six-month cumulative incidence of grade II–IV acute graft-versus-host disease was 46%. Considering the whole cohort, age under 12, busulfan/cyclophosphamide/melphalan conditioning or MUD were associated with poorer 5-year OS. In the cMDS-IB subgroup, pretransplant cytoreductive therapy was associated with a better OS in univariate analysis. This seems to be mainly due to a decreased NRM since no impact on the incidence of relapse was observed. Overall, those data may argue in favor of cytoreduction for cMDS-IB. They need to be confirmed on a larger scale and prospectively.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infections in patients with mantle cell lymphoma","authors":"Kossi D. Abalo,&nbsp;Sara Ekberg,&nbsp;Therese M. L. Andersson,&nbsp;Simon Pahnke,&nbsp;Alexandra Albertsson-Lindblad,&nbsp;Karin E. Smedby,&nbsp;Mats Jerkeman,&nbsp;Ingrid Glimelius","doi":"10.1002/hem3.121","DOIUrl":"10.1002/hem3.121","url":null,"abstract":"<p>Advancements in treatments have significantly improved the prognosis for mantle cell lymphoma (MCL), and there is a growing population of survivors with an increased susceptibility to infections. We assessed the incidence of infections by clinical characteristics and treatment both before and after MCL diagnosis in Sweden. Patients with a diagnosis of MCL ≥ 18 years between 2007 and 2019 were included, along with up to 10 matched comparators. Infectious disease diagnosis and anti-infective drug dispensation were identified by the National Patient and the Prescribed Drug Registers, respectively. Patients and comparators were followed from the diagnosis/matching date until death, emigration, or June 30, 2020. Overall, 1559 patients and 15,571 comparators were followed for a median duration of 2.9 and 5 years, respectively. The infection rate among patients was twofold higher, RRadj = 2.14 (2.01–2.27), contrasted to the comparator group. There was a notable rise in infection rates already 4 years before MCL diagnosis, which reached a fourfold increase in the first year after diagnosis and persisted significantly increased for an additional 8 years. Among patients, 69% (<i>n</i> = 1080) experienced at least one infection during the first year of follow-up. Influenza, pneumonia, other bacterial infections, urinary tract infections, and acute upper respiratory infections were the most frequent. Notably, MCL remained to be the primary leading cause of death among patients (57%, <i>n</i> = 467/817). Infections as the main cause of death were rare (2.6%, <i>n</i> = 21). Our study highlights the importance of thoroughly assessing infectious morbidity when appraising new treatments. Further investigations are warranted to explore strategies for reducing infectious disease burden.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibrinogen-like 1: A hepatokine linking liver physiology to hematology","authors":"Jean Personnaz,&nbsp;Hervé Guillou,&nbsp;Léon Kautz","doi":"10.1002/hem3.115","DOIUrl":"10.1002/hem3.115","url":null,"abstract":"<p>A recent study identified the critical contribution of the hepatokine FGL1 to the regulation of iron metabolism during the recovery from anemia. FGL1 is secreted by hepatocytes in response to hypoxia to sequester BMP ligands and repress the transcription of the iron-regulatory hormone hepcidin. This process ensures the proper supply of iron to the bone marrow for new red blood cell synthesis and the restoration of physiological oxygen levels. FGL1 may therefore contribute to the recovery from common anemias and cause iron overload in chronic anemias with ineffective erythropoiesis, such as ß-thalassemia, dyserythropoietic anemia, and myelodysplastic syndromes. However, FGL1 has also been described as a regulator of hepatocyte proliferation, glucose homeostasis, and insulin signaling, as well as a mediator of liver steatosis and immune evasion. Chronic exposure to elevated levels of FGL1 during anemia may therefore have systemic metabolic effects besides iron regulation and erythropoiesis. Here, we are providing an overview of the proposed functions of FGL1 in physiology and pathophysiology.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11223652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting","authors":"Adrián Alegre,&nbsp;Mercedes Gironella,&nbsp;Fernando Escalante,&nbsp;Juan M. Bergua,&nbsp;Carmen Martínez-Chamorro,&nbsp;Aurelio López,&nbsp;Esther González,&nbsp;Abelardo Bárez,&nbsp;Nieves Somolinos,&nbsp;Ernesto P. Persona,&nbsp;Alexia S. Cabrera,&nbsp;Alfons Soler,&nbsp;Belén I. Rodríguez,&nbsp;Joaquín M. López,&nbsp;Yolanda González,&nbsp;Verónica C. Giménez,&nbsp;Antonia Sampol,&nbsp;Carolina Muñoz,&nbsp;David Vilanova,&nbsp;Marta Durán,&nbsp;Carlos Fernández de Larrea,&nbsp;Spanish Myeloma Group (GEM_PETHEMA)","doi":"10.1002/hem3.81","DOIUrl":"https://doi.org/10.1002/hem3.81","url":null,"abstract":"<p>Recommendations regarding the best time to start treatment in patients with relapsed/refractory multiple myeloma (RRMM) after biological relapse/progression (BR) are unclear. This observational, prospective, multicenter registry aimed to evaluate the impact on time to progression (TTP) of treatment initiation at BR versus at symptomatic clinical relapse (ClinR) based on the Spanish routine practice in adult patients with RRMM. Patients had two or less previous treatment lines and at least one previous partial response. Baseline characteristics and treatment outcomes were recorded, and survival was analyzed. Of 225 patients, 110 were treated at BR (TxBR group) and 115 at ClinR (TxClinR group) according to the investigators' criteria. The proportion of patients with higher ECOG, previous noncomplete remission (CR), and second relapse were significantly higher in the TxBR group compared to the TxClinR group. TheTxClinR group showed improved outcomes, including TTP, compared to the TxBR group. Progression-free survival increased in the TxClinR group (56.2 months) compared to the TxBR group (32.5 months) (<i>p</i> = 0.0137), and median overall survival also increased (<i>p</i> = 0.0897). Median TTP was significantly longer in patients relapsing from a CR (50.4 months) and in their first relapse (38.7 months) compared to those relapsing from a non-CR response (32.9 months) and in their second relapse (25.2 months). Physicians seemed to start treatment earlier in RRMM patients with poor prognosis features. Previous responses to anti-MM treatment and the number of prior treatment lines were identified as prognosis factors, whereby relapse from CR and first relapse were associated with a longer time to progression.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.81","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes","authors":"Kazimierz Groen,&nbsp;Febe Smits,&nbsp;Kazem Nasserinejad,&nbsp;Mark-David Levin,&nbsp;Josien C. Regelink,&nbsp;Gert-Jan Timmers,&nbsp;Esther G. M. de Waal,&nbsp;Matthijs Westerman,&nbsp;Gerjo A. Velders,&nbsp;Koen de Heer,&nbsp;Rineke B. L. Leys,&nbsp;Roel J. W. van Kampen,&nbsp;Claudia A. M. Stege,&nbsp;Maarten R. Seefat,&nbsp;Inger S. Nijhof,&nbsp;Ellen van der Spek,&nbsp;Saskia K. Klein,&nbsp;Niels W. C. J. van de Donk,&nbsp;Paula F. Ypma,&nbsp;Sonja Zweegman","doi":"10.1002/hem3.85","DOIUrl":"10.1002/hem3.85","url":null,"abstract":"&lt;p&gt;In 2015, the International Myeloma Working Group (IMWG) introduced a frailty index (IMWG-FI), as a means to quantify fragility of patients with multiple myeloma (MM). This index categorizes patients into three groups: fit, intermediate-fit, or frail, based on age, comorbidities, and the level of assistance for (instrumental) daily activities ((i)ADL). Scores on the IMWG-FI range from zero to five points. A score of zero designates patients as fit, a score of one indicates intermediate-fit, and a score between two and five denotes frail. Three-year overall survival rates were 84% in fit patients, 76% in intermediate-fit patients (hazard ratio [HR]: 1.61; 95% confidence interval (CI): 1.02–2.56; &lt;i&gt;p&lt;/i&gt; = 0.042). and 57% in frail patients (HR: 3.57; 95% CI: 2.37–5.39; &lt;i&gt;p&lt;/i&gt; &lt; 0.001). In addition, frail patients had a significantly inferior progression-free survival (PFS), a higher tendency to discontinue treatment, and experienced more nonhematologic toxicity, compared to fit patients, which was found to be independent of ISS stage, chromosomal abnormalities, and type of therapy.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;In response to the time-consuming nature and feasibility challenges of assessing the (i)ADL scales in clinical studies, the Simplified Frailty Index (Simplified-FI) emerged in 2020. It substitutes daily activities with the World Health Organization Performance Status (WHO-PS). Also the Simplified-FI underscored that frail patients faced an adverse outcome.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Post hoc frailty subgroup analyses in the MAIA and the ALCYONE trials, utilizing the Simplified-FI showed that frail patients had an inferior OS (41.2 months) compared to non-frail (fit and intermediate-fit combined; 70.1 months) patients, particularly evident in the daratumumab-arm of both studies (HR: 1.86; 95% CI: 1.63–2.12; &lt;i&gt;p&lt;/i&gt; &lt; 0.0001).&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;While both the IMWG-FI and the Simplified-FI categorize patients as fit, intermediate-fit, or frail, the exact alignment of these groups remains uncertain. The question is whether physician-reported WHO-PS can actually replace patient-reported (i)ADL, which better reflects underlying physical, cognitive, or functional problems. There is reason to question concordance as variances in patient outcomes under the same treatment regimen have been noted, depending on which frailty index was employed. For example, intermediate-fit patients, as classified by the Simplified-FI, achieved a median PFS of over 36 months with continuous lenalidomide/dexamethasone in the MAIA study, while patients classified as intermediate-fit according to the IMWG-FI treated with the same regimen in an Italian study had a median PFS of only 18.3 months, suggesting that the Simplified-FI identifies a less vulnerable intermediate-fit patient population.&lt;span&gt;&lt;sup&gt;3, 5&lt;/sup&gt;&lt;/span&gt; Given expert recommendations advocating for treatment adjustments based on frailty, it is crucial to acknowledge potential dispa","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11223651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stage-adapted treatment of HIV-associated Hodgkin lymphoma: Long-term results of a prospective, multicenter study","authors":"Marcus Hentrich,&nbsp;Markus Müller,&nbsp;Christoph Wyen,&nbsp;Anna Pferschy,&nbsp;Vindi Jurinovic,&nbsp;Jan Siehl,&nbsp;Jürgen K. Rockstroh,&nbsp;Dirk Schürmann,&nbsp;Christian Hoffmann,&nbsp;for the German HIV-Related Lymphoma Study Group","doi":"10.1002/hem3.68","DOIUrl":"10.1002/hem3.68","url":null,"abstract":"<p>Results of a prospective study of stage-adapted treatment of human immunodeficiency virus (HIV)-associated Hodgkin lymphoma (HIV-HL) showed a 2-year overall survival (OS) of 90.7% with no significant difference between early favorable (EF), early unfavorable (EU), and advanced HL. Patients with EF HIV-HL received two to four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation, those with EU HIV-HL received four cycles of ABVD or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) baseline + 30 Gy IF, and six to eight cycles of BEACOPP baseline were administered in advanced disease. The objective of the present analysis is to determine long-term outcomes of HIV-HL. Of 108 patients, 23 (21%) had EF HL, 14 (13%) had EU HL, and 71 (66%) had advanced-stage HL. After a median follow-up of 9.14 (range, 0–12.9) years, there were five primary refractory HL patients (5%) and 11 relapses (10%), of which seven were late relapses (&gt;2 years). A second primary malignancy (SPM) occurred in 10 patients after a median of 7.3 years (range, 1.5–10.7) from HL diagnosis. The 10-year OS for patients with EF, EU, and advanced HL was 95.7%, 84.6%, and 76.1%, respectively. By multivariate analysis, Center for Disease Control and Prevention category C (hazard ratio [HR] 3.00, 95% confidence interval [CI]: 1.16–7.74, <i>p</i> = 0.023) and achievement of complete remission were significant for OS (HR 0.03, 95% CI: 0.01–0.08, <i>p</i> = 2.45 × 10⁻⁹). In conclusion, a stage-adapted treatment approach for HIV-HL is highly effective with long-term survival rates similar to those reported in HIV-uninfected HL. However, the risk for late relapse and SPM is significant.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: A high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker","authors":"Emma Kroeze,&nbsp;Michelle M. Kleisman,&nbsp;Lennart A. Kester,&nbsp;Marijn A. Scheijde-Vermeulen,&nbsp;Edwin Sonneveld,&nbsp;Jessica G. C. Buijs-Gladdines,&nbsp;Melanie M. Hagleitner,&nbsp;Friederike A. G. Meyer-Wentrup,&nbsp;Margreet A. Veening,&nbsp;Auke Beishuizen,&nbsp;Jules P. P. Meijerink,&nbsp;Jan L. C. Loeffen,&nbsp;Roland P. Kuiper","doi":"10.1002/hem3.117","DOIUrl":"10.1002/hem3.117","url":null,"abstract":"<p>Twenty percent of children with T-cell lymphoblastic lymphoma (T-LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low-risk subgroup in pediatric T-LBL, yet these high-risk patients who need intensified or alternative treatment options remain undetected. Therefore, there is an urgent need to recognize these high-risk T-LBL patients through identification of molecular characteristics and biomarkers. By using RNA sequencing which was performed in 29/49 T-LBL patients who were diagnosed in the Princess Maxima Center for Pediatric Oncology between 2018 and 2023, we discovered a previously unknown high-risk biological subgroup of children with T-LBL. This subgroup is characterized by <i>NOTCH1</i> gene fusions, found in 21% of our T-LBL cohort (6/29). All patients presented with a large mediastinal mass, pleural/pericardial effusions, and absence of blasts in the bone marrow, blood, and central nervous system. Blood CCL17 (C-C Motif Chemokine Ligand 17, TARC) levels were measured at diagnosis in 26/29 patients, and all six patients with <i>NOTCH1</i> gene fusions patients exclusively expressed highly elevated blood CCL17 levels, defining a novel and previously not known clinically relevant biomarker for T-cell lymphoblastic lymphoma. Four out of these six patients relapsed during therapy, a fifth developed a therapy-related acute myeloid leukemia during maintenance therapy. These data indicate that T-LBL patients with a <i>NOTCH1</i> fusion have a high risk of relapse which can be easily identified using a blood CCL17 screening at diagnosis. Further molecular characterization through <i>NOTCH1</i> gene fusion analysis offers these patients the opportunity for treatment intensification or new treatment strategies.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells","authors":"Gloria Iacoboni,&nbsp;Mario A. Sánchez-Salinas,&nbsp;Kai Rejeski,&nbsp;Ana Á. Martín-López,&nbsp;Mi Kwon,&nbsp;Víctor Navarro,&nbsp;Katarzyna A. Jalowiec,&nbsp;Rafael Hernani,&nbsp;Juan L. Reguera-Ortega,&nbsp;Laura Gallur,&nbsp;Viktoria Blumenberg,&nbsp;María Herrero-García,&nbsp;Claire Roddie,&nbsp;Ana Benzaquén,&nbsp;Javier Delgado-Serrano,&nbsp;Rebeca Bailén,&nbsp;Cecilia Carpio,&nbsp;Paula Amat,&nbsp;Lucia López-Corral,&nbsp;Lourdes Martín-Martín,&nbsp;Mariana Bastos,&nbsp;Marion Subklewe,&nbsp;Maeve O'Reilly,&nbsp;Pere Barba","doi":"10.1002/hem3.86","DOIUrl":"10.1002/hem3.86","url":null,"abstract":"<p>Bridging therapy (BT) after leukapheresis is required in most relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients receiving chimeric antigen receptor (CAR) T cells. Bendamustine-containing regimens are a potential BT option. We aimed to assess if this agent had a negative impact on CAR-T outcomes when it was administered as BT. We included R/R LBCL patients from six centers who received systemic BT after leukapheresis from February 2019 to September 2022; patients who only received steroids or had pre-apheresis bendamustine exposure were excluded. Patients were divided into two BT groups, with and without bendamustine. Separate safety and efficacy analyses were carried out for axi-cel and tisa-cel. Of 243 patients who received BT, bendamustine (benda) was included in 62 (26%). There was a higher rate of BT progressors in the non-benda group (62% vs. 45%, <i>p</i> = 0.02). Concerning CAR-T efficacy, complete responses were comparable for benda versus non-benda BT cohorts with axi-cel (70% vs. 53%, <i>p</i> = 0.12) and tisa-cel (44% vs. 36%, <i>p</i> = 0.70). Also, 12-month progression-free and overall survival were not significantly different between BT groups with axi-cel (56% vs. 43% and 71% vs. 63%) and tisa-cel (25% vs. 26% and 52% vs. 48%); there were no differences when BT response was considered. CAR T-cell expansion for each construct was similar between BT groups. Regarding safety, CRS G ≥3 (6% vs. 6%, <i>p</i> = 0.79), ICANS G ≥3 (15% vs. 17%, <i>p</i> = 0.68), severe infections, and neutropenia post-infusion were comparable among BT regimens. BT with bendamustine-containing regimens is safe for patients requiring disease control during CAR T-cell manufacturing.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “New approaches in gene therapy for sickle cell disease, moving in vivo”","authors":"","doi":"10.1002/hem3.107","DOIUrl":"https://doi.org/10.1002/hem3.107","url":null,"abstract":"<p>Kent DG. New approaches in gene therapy for sickle cell disease, moving in vivo. <i>HemaSphere</i>. 2024;8:e43.</p><p>In paragraph 2, the final sentence included the text “…involves large granulocyte-macrophage progenitor-level virus protection…”, which was incorrect. This should have read “Therapies that might remove the in vitro component, which involves substantial good manufacturing practice virus production and extensive quality control regimens, would therefore be of great utility and the field of in vivo therapies has understandably garnered intense interest”.</p><p>We apologize for this error.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 6","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.107","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141453601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}